A 32-year-old male, known case of chronic myeloid leukemia (CML) on Imatinib with irregular compliance for 6 years, presented with painless swellings over the scalp, face and trunk for 3-weeks. He had non-tender, purplish nodules and plaques of varying sizes over the scalp, face and trunk giving “blueberry muffin” appearance (Fig. 1a). Hemoglobin was 8.3 g/dL; TLC 66,900/mm3 and platelets 70,000/mm3. Biopsy from skin nodule was suggestive of leukemia cutis (Fig. 2a, b). Bone marrow showed CML in chronic phase (Fig. 2c, d). Because of poor finances, he was counseled regarding compliance and imatinib dose was increased to 800 mg/day. Six weeks later, the complete hematological response was achieved, and skin lesions gradually resolved to hyperpigmented macules (Figure 1b).
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.